10-Q: Plexus Corp. Reports Lower Sales and Profitability in First Quarter of Fiscal 2024 Amidst Market Headwinds

Plexus Corp. experienced a decrease in net sales and profitability in the first quarter of fiscal 2024 due to market-driven inventory corrections and weaker demand in certain sectors.

Summary

• Plexus Corp.'s net sales for the first quarter of fiscal 2024 decreased by 10.2% to $982.6 million compared to $1,093.9 million in the same period last year.
• The company's gross profit also declined by 12.9% to $88.1 million, with a gross margin of 9.0%, down from 9.3% year-over-year.
• Operating income decreased by 21.1% to $45.2 million, and net income fell by 30.8% to $29.2 million.
• Diluted earnings per share were $1.04, compared to $1.49 in the prior year.
• The company experienced market-driven inventory corrections at customers and weaker demand in the Healthcare/Life Sciences and Industrial sectors.
• Plexus anticipates a material and unfavorable impact on its tax holidays and effective tax rate beginning in fiscal 2025 due to the implementation of a global minimum tax.
• The company's cash and cash equivalents and restricted cash were $232 million, while debt, finance lease obligations and other financing were $443 million.
• Borrowings under the Credit Facility were $243.0 million, leaving $257 million available for use.

Sentiment

Score: 4

Explanation: The document presents a negative outlook due to decreased sales and profitability, along with concerns about future tax impacts and market conditions. While the company has some positive aspects, the overall tone is cautious and indicates challenges ahead.

Positives

• The EMEA segment saw a 36.4% increase in net sales, driven by new customer production ramps and increased end-market demand.
• The Aerospace/Defense sector experienced a 24.8% increase in net sales due to increased customer end-market demand.
• The company has $257 million available under its revolving credit facility.
• The company has a share repurchase program in place.

Negatives

• Net sales decreased by 10.2% year-over-year, primarily due to market-driven inventory corrections and weaker demand.
• Gross profit and operating income decreased by 12.9% and 21.1%, respectively.
• Net income declined by 30.8% compared to the same period last year.
• The Healthcare/Life Sciences sector saw a 21.9% decrease in net sales.
• The Industrial sector experienced a 7.9% decrease in net sales.
• The company anticipates a material and unfavorable impact on its tax holidays and effective tax rate beginning in fiscal 2025 due to the implementation of a global minimum tax.
• The company's annualized cash cycle increased by 12 days compared to the prior year.

Risks

• The company is experiencing market-driven inventory corrections at customers and weaker demand in certain sectors.
• Global supply chain constraints continue to impact the company's ability to procure components on a timely basis.
• The implementation of a global minimum tax is expected to materially and unfavorably impact the company's tax holidays and effective tax rate beginning in fiscal 2025.
• Increased borrowing under the Credit Facility and rising interest rates could increase interest expense.
• The company faces risks related to customer delays, changes, cancellations, or forecast inaccuracies.
• There are risks associated with excess and obsolete inventory.
• The company is exposed to foreign currency exchange rate risk and interest rate risk.

Future Outlook

The company expects market-driven inventory corrections and weaker demand in certain sectors to be a near-term challenge that will lessen later in fiscal 2024. The company anticipates a material and unfavorable impact on its tax holidays and effective tax rate beginning in fiscal 2025 due to the implementation of a global minimum tax. Capital expenditures for fiscal 2024 are estimated to be between $100.0 million and $120.0 million.

Management Comments

• The company has experienced market-driven inventory corrections at customers and weaker demand in the Healthcare/Life Sciences and Industrial sectors.
• The company believes its balance sheet is positioned to support the potential future challenges presented by the macro-economic pressures it is facing.
• The company's goal is to create value for its shareholders by generating ROIC in excess of its WACC.

Industry Context

The results reflect broader challenges in the electronic manufacturing services industry, including supply chain disruptions, inventory corrections, and fluctuating demand. The company's performance is impacted by global economic conditions and specific sector trends, particularly in healthcare and industrial markets.

Comparison to Industry Standards

• Plexus's decrease in revenue and profitability is consistent with challenges faced by other EMS providers in the current economic climate.
• Companies like Jabil and Flex have also reported similar pressures related to supply chain and demand fluctuations.
• Plexus's ROIC of 10.3% is below its target of 15%, indicating a need for improved capital efficiency.
• The company's cash cycle days have increased, which is a concern compared to industry benchmarks that emphasize efficient working capital management.

Stakeholder Impact

• Shareholders will be impacted by the decrease in profitability and earnings per share.
• Employees may be affected by potential restructuring or cost-cutting measures.
• Customers may experience some delays or changes in service due to supply chain constraints.
• Suppliers may be impacted by changes in the company's procurement patterns.

Next Steps

• The company will continue to monitor market conditions and adjust its operations accordingly.
• The company will focus on managing its working capital and inventory levels.
• The company will continue to evaluate and consider various financing alternatives to supplement its financial resources.
• The company will commence the 2024 share repurchase program upon completion of the 2023 program.

Key Dates

Keywords

Electronic Manufacturing Services, EMS, supply chain, manufacturing, net sales, gross profit, operating income, net income, earnings per share, ROIC, inventory, market corrections, global minimum tax, share repurchase